Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers 第一阶段：每周两次脉冲剂量和每天两次小剂量厄洛替尼作为egfr突变型肺癌患者初始治疗的研究.pdfVIP

Annals of Oncology 0: 1–7, 2016 original article doi:10.1093/annonc/mdw556 Published online 25 October 2016 Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers† 1,2, 3 1 4,5 6 6 1,2 H. A. Yu *, C. Sima , D. Feldman , L. L. Liu , B. Vaitheesvaran , J. Cross , C. M. Rudin , 1,2 7 4,5 1,2 M. G. Kris , W. Pao , F. Michor G. J. Riely 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York; 2 Weill Cornell Medical College, New York; 3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York; 4Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute; 5Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA; 6Donald B. and Catherine C. Marron Cancer Metabolism Center, Sloan Kettering Institute, Sloan Kettering Cancer Center, New York; 7Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN Received 16 June 2016; revised 29 September 2016; accepted 20 October 2016 Background: Patients with EGFR-mutant lung cancers treated with EGFR tyrosine kinase inhibitors (TKIs) develop clinical resistance, most commonly with acquisition of EGFR T790M. Evolutionary modeling suggests that a schedule